Publication Date:
2019-11-13
Description:
Introduction Rozanolixizumab targets the human neonatal Fc receptor (FcRn). By blocking IgG recycling, this first-in-class subcutaneously (SC) infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. We report the completed Phase II, open-label study of rozanolixizumab in patients (pts) with primary immune thrombocytopenia (ITP; NCT02718716). Methods Eligibility: ≥18 yrs old; primary ITP ≥3 months (persistent/chronic); platelet count
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink